Breast Cancer Research and Treatment

, Volume 127, Issue 3, pp 841–844 | Cite as

Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab

  • Mafalda Oliveira
  • Sofia Braga
  • José Luís Passos-Coelho
  • Ricardo Fonseca
  • João Oliveira
Brief Report

Abstract

Trastuzumab, a monoclonal antibody against the HER2 receptor, is a major breakthrough in the treatment of HER2+ breast cancer. However, its high molecular weight precludes it from crossing the intact blood–brain barrier, making the central nervous system a sanctuary to HER2+ breast cancer metastases. We prospectively assessed functional outcome and toxicity of administering trastuzumab directly into the cerebrospinal fluid of a patient with leptomeningeal carcinomatosis (LC) and brain metastases from HER2+ breast cancer that had already been treated with other intrathecal chemotherapy, with no benefit. Upon signed informed consent, weekly lumbar puncture with administration of trastuzumab 25 mg was begun to a 44 year-old women with metastatic breast cancer (lymph node, bone, lung, and liver involvement) previously treated with tamoxifen, letrozole, anthracyclines, taxanes, capecitabine, intravenous trastuzumab, and lapatinib. She received 67 weekly administrations of intrathecal trastuzumab with marked clinical improvement and no adverse events. She survived 27 months after LC diagnosis. A complete leptomeningeal response, with no evidence of leptomeningeal metastasis at necropsy, was achieved. We believe that intrathecal trastuzumab administration should be prospectively evaluated to confirm clinical activity and optimize dose, schedule, and duration of treatment.

Keywords

Intrathecal trastuzumab Leptomeningeal carcinomatosis HER2+ breast cancer 

References

  1. 1.
    Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103–119PubMedCrossRefGoogle Scholar
  2. 2.
    Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944PubMedCrossRefGoogle Scholar
  3. 3.
    Bidard FC, Guilhaume MN, Gauthier H, Cottu PH, Dieras V, Pierga JY (2009) Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol 93:287–288PubMedCrossRefGoogle Scholar
  4. 4.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  5. 5.
    Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116:302–308PubMedCrossRefGoogle Scholar
  6. 6.
    Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744–4749PubMedGoogle Scholar
  7. 7.
    Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11(Suppl 1):4–12PubMedCrossRefGoogle Scholar
  8. 8.
    Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2009) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116:302–308CrossRefGoogle Scholar
  9. 9.
    Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs 18:23–28PubMedCrossRefGoogle Scholar
  10. 10.
    Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2:235PubMedGoogle Scholar
  11. 11.
    Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, Aristei C, Floridi P (2009) Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 63:1157–1159PubMedCrossRefGoogle Scholar
  12. 12.
    Shojima K, Suzuki E, Saito K, Sekine S, Kitagawa D, Aruga T, Saji S, Kuro K (2008) Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol 26 (May 20 suppl; abstr 1138)Google Scholar
  13. 13.
    Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC (2009) Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 20:792–795PubMedCrossRefGoogle Scholar
  14. 14.
    Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978–1980PubMedCrossRefGoogle Scholar
  15. 15.
    Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778–780PubMedCrossRefGoogle Scholar
  16. 16.
    Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V (2008) Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19:832–836PubMedCrossRefGoogle Scholar
  17. 17.
    Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, Schoenberg S, Heinemann V (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373–1377PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Mafalda Oliveira
    • 1
  • Sofia Braga
    • 2
  • José Luís Passos-Coelho
    • 1
  • Ricardo Fonseca
    • 3
  • João Oliveira
    • 1
  1. 1.Medical Oncology DepartmentInstituto Português de Oncologia de Lisboa Francisco GentilLisbonPortugal
  2. 2.Instituto Gulbenkian de CiênciaOeirasPortugal
  3. 3.Pathology DepartmentInstituto Português de Oncologia de Lisboa Francisco GentilLisbonPortugal

Personalised recommendations